Abstract:Malignant pleural effusion (MPE) is an exudative effusion with malignant cells. MPE is a common symptom and accompanying manifestation of metastatic disease. It affects up to 15% of all patients with cancer and is the most common in lung, breast cancer, lymphoma, gynecological malignancies and malignant mesothelioma. In the last year, many studies were performed focusing on the pathophysiological mechanisms of MPE. With the advancement in molecular techniques, the importance of tumor-host cell interactions is becoming more apparent. Additionally, the process of pathogenesis is greatly affected by activating mutations of EGFR, KRAS, PIK3CA, BRAF, MET, EML4/ALK and RET, which correlate with an increased incidence of MPE. Considering all these changes, the authors aim to present a literature review of the newest findings, review of the guidelines and pathophysiological novelties in this field. Review of the just recently, after seven years published, practice guidelines, as well as analysis of more than 70 articles from the Pubmed, Medline databases that were almost exclusively published in indexed journals in the last few years, have relevance and contribute to the better understanding of the presented topic. MPE still presents a severe medical condition in patients with advanced malignancy. Recent findings in the field of pathophysiological mechanisms of MPE emphasize the role of molecular factors and mutations in the dynamics of the disease and its prognosis. Treatment guidelines offer a patient-centric approach with the use of new scoring systems, an out of hospital approach and ultrasound. The current guidelines address multiple areas of interest bring novelties in the form of validated prediction tools and can, based on evidence, improve patient outcomes. However, the role of biomarkers in a clinical setting, possible new treatment modalities and certain specific situations still present a challenge for new research.

The genetic susceptibility in the development of malignant pleural mesothelioma: somatic and germline variants, clinicopathological features and implication in practical medical/surgical care: a narrative review

Medical and surgical care of mesothelioma patients and their relatives carrying germline BAP1 mutations

Genetic analysis of familial predisposition in the pathogenesis of malignant pleural mesothelioma

Surgical phenotype of patients with peritoneal mesothelioma and a germline mutation

Biomarker-guided Targeted and Immunotherapies in Malignant Pleural Mesothelioma

Molecular Changes in Mesothelioma With an Impact on Prognosis and Treatment

Pleural mesothelioma (PMe): The evolving molecular knowledge of a rare and aggressive cancer

Expression status of candidate genes in mesothelioma tissues and cell lines

A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma.

Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma

Germline TP53 pathogenic variants and breast cancer: a narrative review

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy

Nevermore without the Pathology Report

Malignant pleural effusion: current understanding and therapeutic approach

Therapeutic Landscape of Malignant Pleural Mesothelioma: Collateral Vulnerabilities and Evolutionary Dependencies in the Spotlight

Mesothelioma in situ of the peritoneum: report of three cases and review of the literature

MA17.08 Whole-Genome CRISPR Screening Reveals Genetic Vulnerabilities and Therapeutic Targets in Malignant Pleural Mesothelioma

MA06.05 Targeting Anti-Apoptotic Mechanisms in Malignant Pleural Mesothelioma

Malignant Pleural Effusion and Its Current Management: A Review

Emerging New Targets in Systemic Therapy for Malignant Pleural Mesothelioma

Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment